Evidence mapPaperPMID 35899381Full record

ArticleThe American journal of psychiatry2022

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005-2019.

Deborah S Hasin, Andrew J Saxon, Carol Malte, Mark Olfson, Katherine M Keyes, Jaimie L Gradus, Magdalena Cerdá, Charles C Maynard, Salomeh Keyhani, Silvia S Martins and 4 more

Open access · greenAbstract read
In one paragraph

Article in The American journal of psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Deborah S HasinDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Andrew J SaxonDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Carol MalteDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Mark OlfsonDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Katherine M KeyesDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Jaimie L GradusDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Magdalena CerdáDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Charles C MaynardDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Salomeh KeyhaniDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Silvia S MartinsDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
David S FinkDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Ofir LivneDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Zachary MannesDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Melanie M WallDepartment of Epidemiology (in Psychiatry) (Hasin), Department of Epidemiology (Olfson, Keyes, Martins, Livne, Mannes), and Department of Psychiatry (Olfson), Columbia University, New York; New York State Psychiatric Institute, New York (Hasin, Olfson, Fink, Wall); VA Puget Sound Health Care System, Seattle (Saxon, Malte, Maynard); Department of Psychiatry and Behavioral Sciences (Saxon) and Department of Health Systems and Population Health (Maynard), University of Washington, Seattle; Department of Epidemiology, Boston University, Boston (Gradus); Department of Population Health, New York University, New York (Cerdá); San Francisco VA Health System and Division of General Internal Medicine, University of California at San Francisco (Keyhani); Department of Biostatistics (in Psychiatry), Columbia University Medical Center, New York (Wall).
Sax Institute · AU

Funding

Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024R01DA048860 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI DEBORAH S HASIN · 2023 to 2023
$746k
Substance Abuse Epidemiology Training Program (SAETP) at Columbia UniversityT32DA031099 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$582k
NIDA NIH HHS R01 DA048860NIDA NIH HHS T32 DA031099
6 · The paper itself

Abstract

objectiveIn the United States, adult cannabis use has increased over time, but less information is available on time trends in cannabis use disorder. The authors used Veterans Health Administration (VHA) data to examine change over time in cannabis use disorder diagnoses among veterans, an important population subgroup, and whether such trends differ by age group (<35 years, 35-64 years, ≥65 years), sex, or race/ethnicity.

methodsVHA electronic health records from 2005 to 2019 (range of Ns per year, 4,403,027-5,797,240) were used to identify the percentage of VHA patients seen each year with a cannabis use disorder diagnosis (ICD-9-CM, January 1, 2005-September 30, 2015; ICD-10-CM, October 1, 2015-December 31, 2019). Trends in cannabis use disorder diagnoses were examined by age and by race/ethnicity and sex within age groups. Given the transition in ICD coding, differences in trends were tested within two periods: 2005-2014 (ICD-9-CM) and 2016-2019 (ICD-10-CM).

resultsIn 2005, the percentages of VHA patients diagnosed with cannabis use disorder in the <35, 35-64, and ≥65 year age groups were 1.70%, 1.59%, and 0.03%, respectively; by 2019, the percentages had increased to 4.84%, 2.86%, and 0.74%, respectively. Although the prevalence of cannabis use disorder was consistently higher among males than females, between 2016 and 2019, the prevalence increased more among females than males in the <35 year group. Black patients had a consistently higher prevalence of cannabis use disorder than other racial/ethnic groups, and increases were greater among Black than White patients in the <35 year group in both periods.

conclusionsSince 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public should be educated about the increases in cannabis use disorder in general in the United States, including among patients treated at the VHA.

Indexed as

CannabisMarijuana AbuseSubstance-Related DisordersVeteransAdultFemaleHumansMaleUnited StatesUnited States Department of Veterans AffairsVeterans HealthCannabisCannabis Use DisorderEpidemiologySubstance-Related and Addictive DisordersVeterans

Identifiers

PMID35899381
PMCPMC9529770
OpenAlexW4288077489

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.